QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Perspective Therapeutics, Inc. (CATX)

Healthcare

No action
Fundamental
2
Sentiment
3
Technical
2

Do Nothing: fundamentalScore 2 is below the required floor of 3 (and the 20-day average dollar volume of $4.67M is below the $5.00M liquidity floor), so no new long is admissible regardless of the chart; both entry types were evaluated — no pullback limit qualifies (countertrend: price 0.8535 below SMA50 2.02 with MACD −0.36, and below a declining SMA200 3.41 without a reclaim) and no breakout stop qualifies for production (a stop above 0.95 would give R/R ~1.86 but is barred by the same fundamental and liquidity floors, and one above the 1.02 swing high gives only R/R ~1.27).

Analysis as of 2026-11-17· more than 2 trading days ago

Company overview

Perspective Therapeutics, Inc. develops, manufactures, and markets radiopharmaceutical products and medical devices aimed at treating cancer. Its flagship product, CS-1 Cesium-131 brachytherapy seeds, is used for various cancers including prostate, brain, and lung. The company operates globally and is headquartered in Richland, Washington.

Fundamental

weak
Fundamental2
Speculative fundamentals

Perspective Therapeutics has a strong cash position but lacks revenue and faces high dilution, making it speculative.

Pre-revenue radiopharma developer with a fortress-like net-cash position (~$198 million versus a $103 million market cap, runway into 2028) but no product revenue, a ~$123 million trailing net loss, an accelerating ~$108 million annual operating cash burn, 62% share dilution in twelve months and binary clinical risk. Fundamentals read as speculative, not investable on a short horizon.

Sentiment

fair
Sentiment3
Mixed sentiment

Sentiment is mixed with recent insider buying and clinical data offset by earnings misses and target cuts.

Dominant in-window catalyst is the announced Q3 2026 print (2026-11-09) — an EPS and revenue miss with a widening $32.4M net loss and three same-day sell-side price-target cuts (Wedbush $9→$7, Truist $11→$8, Piper $14→$8) — set against two material announced clinical readouts (VMT01 at SITC and VMT-α-NET at NANETS, both 2026-11-06) and a five-insider open-market buying cluster struck at $0.80–$1.00. Media polarity cooled from a positive baseline (+0.30, a single scored item on a degraded pull corroborated by 11 discovered on-topic items) to flat/mixed (+0.05 across 6 scored items), a mild deterioration to flat at moderate confidence; the Red-Flag Screen found no severe flag, but a moderate conflicting-catalyst flag fired and the moderate red-flag cap applies.

Technical

weak
Technical2
Downtrend persists

The stock is in a strong downtrend with no bullish setup, despite a recent oversold bounce.

Bounce-only chart, no bullish confirmation stack. Price is below every trend reference (SMA20 1.13, SMA50 2.02, SMA200 3.41, EMA9 0.91, EMA21 1.21, daily VWAP 0.867) after a collapse from $3.48 on 2026-08-19 to $0.85 — including a −32.9% session on 2026-10-23 and a further −16.2% on 2026-11-03. Momentum is deeply oversold (RSI14 27.48, Williams %R −85.34) and the MACD histogram has turned faintly positive (+0.04 from −0.10 on 2026-11-03), which is a nascent countertrend bounce attempt, but MACD line/signal remain negative (−0.36/−0.40) and ADX14 50.74 read together with price below all MAs describes strong DOWN-trend strength, not accumulation. Volatility is extreme (ATR14 $0.16 = 18.75% of price; StdDev20 0.43) and turnover is fading (3-day average dollar volume ~$2.3M vs 20-day $4.67M). Nothing here qualifies as a 1–15 day bullish setup: the chart scores 2 (weak/oversold-bounce only).

You’re looking at 2026-11-17 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.